Eli Lilly & Co. LLY

Eli Lilly and Company es una empresa de fabricación de medicamentos. La empresa descubre, desarrolla, fabrica y comercializa productos en el segmento de productos farmacéuticos para humanos. Los productos de la empresa incluyen productos para la diabetes y otras endocrinologías, como Baqsimi, Basaglar, Forteo, Humalog, Humatrope, Humulin, Jardiance, Trajenta y Trulicity. Sus productos de inmunología incluyen Olumiant y Taltz. Sus productos de neurociencia incluyen Cymbalta, Emgality, Reyvow, Strattera y Zyprexa. Sus productos de oncología incluyen Alimta, Cyramza, Erbitux y Verzenio. Otros productos incluyen Cialis, para el tratamiento de la disfunción eréctil y la hiperplasia prostática benigna. La empresa fabrica y distribuye sus productos a través de instalaciones en Estados Unidos, Puerto Rico y otros 8 países. Sus productos se venden en aproximadamente 120 países.

Con 1 acción de LLY (USD 1.150,91) habrías recibido USD 6,69 en dividendos en los últimos 12 meses.

• The Motley Fool 2 oct

  Prediction: This Stock Could Double Over the Next 5 Years

  Viking Therapeutics' weight loss drug VK2735 shows strong clinical promise with potential for dual-formulation therapy (injectable followed by oral maintenance). The company raised $500 million to fund pipeline development. With the obesity drug market projected to reach $77 billion by 2030, even a small 1.4% market share could generate $1.2 billion in revenue for Viking's $4 billion market cap, suggesting significant upside potential, though clinical trial risks remain.

  

• Zacks Investment Research 1 oct

  Will Lilly (LLY) Beat Estimates Again in Its Next Earnings Report?

  Eli Lilly (LLY) has demonstrated a strong streak of beating earnings estimates, surpassing consensus by an average of 30.27% over the last two quarters. With a positive Earnings ESP of +0.64% and a Zacks Rank #3 (Hold), the company is well-positioned for another earnings beat in its next quarterly report expected on October 29, 2026. Stocks with this combination of positive Earnings ESP and solid Zacks Rank historically beat consensus estimates nearly 70% of the time.

  

• Zacks Investment Research 1 oct

  Novo's Wegovy Pill Shows Weight Loss After Switching From Injections

  Novo Nordisk's oral Wegovy demonstrated an average 4.1% weight loss after three months in the OCTANE study among patients switching from injectable GLP-1 therapies, with 40.7% achieving at least 5% weight loss. Additionally, CagriSema showed benefits beyond weight reduction, including reduced abdominal, liver, and pancreatic fat while maintaining bone health in diabetes patients.

  

• Zacks Investment Research 1 oct

  Lilly vs. Novo: Inside the Milan EASD Showdown and the ETFs Poised to Win

  At the 2026 EASD conference in Milan, Eli Lilly and Novo Nordisk presented competing clinical data in the weight-loss drug market. Lilly's retatrutide showed 34.9% of patients lost at least 25% of body weight, while Novo countered with cardiovascular safety data for Ozempic. The GLP-1 market is expanding rapidly with over 27% of global adults eligible for these medications, attracting competition from Pfizer, Amgen, and Regeneron. Healthcare ETFs like OZEM, HRTS, and THNR offer diversified exposure to this growing sector.

  

• Zacks Investment Research 1 oct

  ABBV Stock Rises 25% in 6 Months: Time to Buy, Hold or Sell?

  AbbVie's stock has gained 25.4% over six months, driven by strong growth from Skyrizi and Rinvoq, which are expected to generate over $31 billion in combined 2026 sales. The company is successfully navigating Humira's patent expiry through new immunology and neuroscience products. However, challenges include Humira biosimilar erosion, slowing oncology sales, and weakness in the Aesthetics business. Analysts recommend holding the stock (Zacks Rank #3) as long-term prospects remain intact with expected 10% revenue growth in 2026.